Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

New Insights on Neuronal Nicotinic Acetylcholine Receptors as Targets for Pain and Inflammation: A Focus on alpha 7 nAChRs CURRENT NEUROPHARMACOLOGY Bagdas, D., Gurun, M. S., Flood, P., Papke, R. L., Damaj, M. 2018; 16 (4): 415–25

Abstract

Nicotine and nicotinic acetylcholine receptors (nAChRs) have been explored for the past three decades as targets for pain control. The aim of this review is to introduce readers particularly to a7 nAChRs in a perspective of pain and its modulation.Developments for a7 nAChR modulators and recent animal studies related to pain are reviewed.Accumulating evidences suggest that selective ligands for a7 nAChRs hold promise in the treatment of chronic pain conditions as they lack many of side effects associated with other nicotinic receptor types.This review provides the reader recent insights on a7 nAChRs from structure and function to the latest findings on the pharmacology and therapeutic targeting of these receptors for the treatment of pain and inflammation.

View details for PubMedID 28820052